SigVie-002 Setback: Can Sigvotatug Vedotin Still Find its Place in the NSCLC ADC Landscape?
Sigvotatug vedotin (SGN-B6A) is an investigational ADC targeting integrin β6, a cell-surface protein expressed in several epithelial malignancies, including NSCLC. Developed by Seagen, now part of Pfizer, the agent was evaluated against docetaxel in the global, randomized Phase III SigVie-002 study (NCT06012435). The trial enrolled patients with advanced nonsquamous NSCLC whose disease had progressed following prior treatment, with overall survival as the primary endpoint.
The Phase III findings presented at ESMO Congress 2026 did not establish a statistically significant survival advantage for sigvotatug vedotin. Median OS was 11.9 months with the ADC and 11.5 months with docetaxel. Although median progression-free survival (PFS) numerically favored sigvotatug vedotin, the difference was not statistically significant. These findings highlight the challenge of translating target-directed payload delivery and promising earlier-stage activity into a meaningful survival advantage against an active chemotherapy comparator.
|
Key Efficacy and Safety Highlights | |||
|
Category |
Parameter |
Sigvotatug vedotin |
Docetaxel |
|
Efficacy |
Patients randomized |
354 |
349 |
|
Median OS |
11.9 months |
11.5 months | |
|
OS hazard ratio (95% CI) |
0.929 (0.767–1.126) |
Comparator arm | |
|
OS statistical significance |
Not met (p= 0.226) |
Comparator arm | |
|
Median PFS |
4.7 months |
4.2 months | |
|
PFS hazard ratio (95% CI) |
0.844 (0.699–1.019) |
Comparator arm | |
|
Objective response rate |
16% |
13% | |
|
Disease control rate |
69% |
60% | |
|
Safety |
Median duration of response |
8.3 months |
10.1. months |
|
Grade ≥3 treatment-related adverse events |
33% |
36% | |
|
Treatment discontinuation due to treatment-related adverse events |
11% |
9% | |
|
OS: Overall Survival; PFS: Progression-Free Survival; CI: Confidence Interval | |||
Conclusion-
The Phase III SigVie-002 findings represent a setback for sigvotatug vedotin as monotherapy in previously treated nonsquamous NSCLC. The study failed to meet its primary OS endpoint, and the numerical differences in PFS and response rates did not establish a statistically significant overall clinical advantage over docetaxel. Although the exploratory second-line findings provide a rationale for further investigation, they are insufficient to support a change in clinical practice. The next key question is whether earlier-line combination strategies can establish a meaningful role for this IB6-directed ADC. More broadly, the findings underscore that the future of ADCs in NSCLC will depend not simply on target expression or response activity, but on demonstrable improvements in clinically meaningful outcomes.